NCT00289731View on ClinicalTrials.gov

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

PHASE4CompletedINTERVENTIONAL
Enrollment

596

Participants

Timeline

Start Date

November 24, 2003

Primary Completion Date

December 21, 2004

Study Completion Date

December 21, 2004

Conditions
Hepatitis BHepatitis A
Interventions
BIOLOGICAL

TWINRIX™

Intramuscular injection, 3 doses

BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

BIOLOGICAL

HAVRIX™

Intramuscular injection, 2 doses

BIOLOGICAL

HB VAX PRO™

Intramuscular injection, 3 doses

BIOLOGICAL

Vaqta™

Intramuscular injection, 2 doses

Trial Locations (9)

2610

GSK Investigational Site, Wilrijk

23795

GSK Investigational Site, Bad Segeberg

24576

GSK Investigational Site, Bad Bramstedt

25335

GSK Investigational Site, Elmshorn

500 01

GSK Investigational Site, Hradec Králové

03238

GSK Investigational Site, Finsterwalde

01129

GSK Investigational Site, Dresden

09326

GSK Investigational Site, Geringswalde

01796

GSK Investigational Site, Pirna

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY